NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Macrogenics, Inc. MGNX
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$149.5M
▼ 0.3% vs FY2024
EPS · FY25
$-1.18
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-86.9%
Net margin · FY25
-49.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 149.5M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 50 cents on every revenue dollar this year.
Per share
USD -1.18
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-86.9%
Return on equity, FY2025
ROE
Operating margin-48.7%
Net margin-49.9%
Return on assets-28.8%
Each USD of equity lost 87 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+7.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−0.5%
+7.3%
+4.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+12.6%
Change, 10 years+84.4%
The share count grew 13% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 256.8M
total assets, end of FY2025
Total assetsUSD 256.8M
EquityUSD 55.6M
CashUSD 57.2M
Current ratio5.10×
Equity funds 22% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.1
0.1
0.1
0.2
0.1
0.1
0.1
0.1
0.2
0.1
0.1
0.0
0.1
0.1
0.1
Operating income $B
−0.1
−0.1
−0.2
−0.1
−0.2
−0.1
−0.2
−0.2
−0.0
−0.1
−0.0
−0.0
0.0
0.0
0.0
EBITDA $B
−0.1
−0.1
−0.2
−0.1
−0.2
−0.1
−0.2
−0.2
−0.0
−0.1
−0.0
−0.0
0.0
0.0
0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.1
−0.1
−0.0
−0.1
−0.2
−0.1
−0.2
−0.2
−0.0
−0.1
−0.0
−0.0
−0.0
0.0
0.0
EPS, diluted $
−1.18
−1.07
−0.15
−1.95
−3.37
−2.47
·
·
−0.54
−1.69
−0.63
−1.40
−0.04
0.00
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−86.9
−49.9
−6.1
−62.8
−75.5
−49.3
−64.1
−63.3
−6.9
−20.1
−9.3
−38.3
−0.7
·
·
Shares out B
0.06
0.06
0.06
0.06
0.06
0.06
0.05
0.04
0.04
0.03
0.03
0.03
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed